Table 3 Hazard ratios of baseline characteristics for RFS and BCSS (univariate analysis)

Age

215

1.16 (0.46–2.98)

NS

1.11 (0.39–3.16)

NS

pT stage^a

215

 T0

1.0

1.0

 T1

1.58 (0.46–5.46)

NS

1.54 (0.34–7.06)

NS

 T2

2.12 (0.61–7.37)

NS

2.30 (0.51–10.41)

NS

 T3

7.80 (1.74–34.97)

<0.01

11.29(2.06–61.89)

<0.01

 T4

2.64 (0.53–13.10)

NS

8.95 (1.73–46.29)

<0.01

pN stage^a

215

 N0

1.0

1.0

 N1

1.77 (0.66–4.74)

NS

2.38 (0.69–8.23)

NS

 N2 and N3

2.75 (1.01–7.56)

<0.05

4.61 (1.32–16.08)

<0.05

pTNM^a

215

 0–1

1.0

1.0

 2

1.15 (0.41–3.22)

NS

1.63 (0.50–5.30)

NS

 3–4

3.41 (1.39–8.35)

<0.01

3.92 (1.33–11.54)

<0.05

HG

215

 1

1.0

1.0

 2

2.68 (0.56–12.89)

NS

1.65 (0.30–9.01)

NS

 3

26.29(6.25–10.57)

<0.001

21.70(5.11–92.12)

<0.001

Hormone receptor

215

 ER⁺ PR⁺

1.0

1.0

 ER⁺ or PR⁺

1.88 (0.93–3.82)

NS

2.05 (0.94–4.50)

NS

 ER⁻ PR⁻

1.76 (0.76–4.08)

NS

1.95 (0.77–4.89)

NS

Her2

215

 +

0.84 (0.43–1.66)

NS

1.14 (0.56–2.34)

NS

 -

1.0

1.0

Molecular subtype

215

 Luminal A

1.0

1.0

 Luminal B

1.12 (0.53–2.39)

NS

1.32 (0.58–3.00)

NS

 HER2-enriched

0.81 (0.24–2.71)

NS

1.04 (0.30–3.58)

NS

 Triple-negative

2.07 (0.78–5.50)

NS

2.11 (0.70–6.33)

NS

pCR

215

 Yes

1.0

1.0

 No

3.00 (1.92–9.73)

<0.05

9.05 (1.24–65.97)

<0.05

Chemotherapy regimen

215

 TEC

1.0

1.0

 TCH

0.89 (0.67-2.93)

NS

1.65 (0.54-3.42)

NS

 TC

1.19 (0.86–2.25)

NS

1.32 (0.42–2.91)

NS

 EC

1.23 (0.63–2.40)

NS

1.20 (0.58–2.48)

NS

Surgery

215

 Breast-conserving surgery

1.0

1.0

 Modified mastectomy

0.55 (0.27–1.10)

NS

0.46 (0.21–1.03)

NS

Chemotherapy cycles

215

 3

1.0

1.0

 4

1.15 (0.52–2.54)

NS

1.07 (0.47–2.48)

NS

 >4

0.64 (0.17–2.42)

NS

0.76 (0.20–2.88)

NS

NLR

215

 NLR < 2.1

1.0

1.0

 NLR ≥ 2.1

2.11 (1.09–4.11)

<0.05

2.45 (1.13–5.31)

<0.05

CRP (before NAC)

215

1.03 (1.01–1.05)

<0.001

1.03 (1.01–1.06)

<0.01